Mira Pharmaceuticals closes acquisition of SKNY Pharmaceuticals

MIRA Pharmaceuticals (MIRA) has completed its acquisition of SKNY Pharmaceuticals,. As part of the transaction, SKNY fulfilled all closing obligations, contributing $5M in marketable securities to MIRA, further strengthening the Company’s balance sheet. “The successful closing of the SKNY acquisition marks a pivotal milestone for MIRA, both financially and strategically,” said Erez Aminov, CEO of MIRA. “We are expanding our pipeline into obesity and nicotine addiction with SKNY-1, while continuing to advance Ketamir-2 through clinical development and progressing MIRA-55 as a novel approach to inflammatory and nociceptive pain. Together, these programs position MIRA to address major unmet needs across some of the largest healthcare markets.”